- Home
- FLC vs TLSI Comparison
FLC vs TLSI Comparison
Compare FLC & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- TLSI
- Stock Information
- Founded
- FLC 2003
- TLSI 2010
- Country
- FLC United States
- TLSI United States
- Employees
- FLC N/A
- TLSI N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- FLC Finance
- TLSI Health Care
- Exchange
- FLC Nasdaq
- TLSI Nasdaq
- Market Cap
- FLC 180.6M
- TLSI 124.9M
- IPO Year
- FLC N/A
- TLSI N/A
- Fundamental
- Price
- FLC $16.59
- TLSI $4.69
- Analyst Decision
- FLC
- TLSI Strong Buy
- Analyst Count
- FLC 0
- TLSI 6
- Target Price
- FLC N/A
- TLSI $11.75
- AVG Volume (30 Days)
- FLC 37.8K
- TLSI 36.4K
- Earning Date
- FLC 01-01-0001
- TLSI 11-14-2024
- Dividend Yield
- FLC 6.64%
- TLSI N/A
- EPS Growth
- FLC N/A
- TLSI N/A
- EPS
- FLC N/A
- TLSI N/A
- Revenue
- FLC N/A
- TLSI $26,891,000.00
- Revenue This Year
- FLC N/A
- TLSI $60.96
- Revenue Next Year
- FLC N/A
- TLSI $53.65
- P/E Ratio
- FLC N/A
- TLSI N/A
- Revenue Growth
- FLC N/A
- TLSI 67.90
- 52 Week Low
- FLC $12.62
- TLSI $3.50
- 52 Week High
- FLC $15.45
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- FLC 44.20
- TLSI 51.68
- Support Level
- FLC $16.46
- TLSI $4.72
- Resistance Level
- FLC $16.89
- TLSI $5.32
- Average True Range (ATR)
- FLC 0.22
- TLSI 0.31
- MACD
- FLC -0.01
- TLSI 0.01
- Stochastic Oscillator
- FLC 36.00
- TLSI 47.52
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.